Víctor M. Villalobos

Author

Also Known As

Sughey Buenrostro Pérez, V. M. Villalobos, V. Villalobos, V.M. VILLALOBOS, V.M. Villalobos, Victor M Villalobos, Victor M. Villalobos, Victor Manuel Villalobos, Victor Villalobos, Villalobos, Victor M

119

Publications

4.5K

Citations

H-Index

107

Concepts

All Affiliations

University of Colorado Denver Dana-Farber Cancer Institute Memorial Sloan Kettering Cancer Center The University of Texas MD Anderson Cancer Center Institut Gustave Roussy

About

Víctor M. Villalobos is an author at University of Colorado Denver specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	29	2.3K
2	Health Sciences	7	7	630
3	Natural Sciences	6	6	289
4	Engineering	4	4	178
5	Public Health	1	1	43

Víctor M. Villalobos

Publications

3.6K

Citations

H-Index

Page 1

	Year	Citations
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers Branimir I. Šikić, Nehal J. Lakhani, Amita Patnaik, Journal of Clinical Oncology	2019	564
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial José Trigo, Vivek Subbiah, Benjamin Besse, The Lancet Oncology Second-line TreatmentOncologyMetronomic TherapyClinical TrialsPathology	2020	433
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study Mrinal M. Gounder, Patrick Schöffski, Robin L. Jones, The Lancet Oncology Tumor BiologyMedicineBasket StudyPathologyImmune Checkpoint Inhibitor	2020	383
NCCN Guidelines Insights: Bone Cancer, Version 2.2017 J. Sybil Biermann, Warren Chow, Damon R. Reed, Journal of the National Comprehensive Cancer Network Bone DiseaseMedicineCancer ManagementNccn Guidelines InsightsBone Cancer	2017	291
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma William D. Tap, Víctor M. Villalobos, Gregory M. Coté, Journal of Clinical Oncology	2020	149
Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors Howard A. Burris, Jeffrey R. Infante, Stephen M. Ansell, Journal of Clinical Oncology Novel TherapyPurpose Cd27MedicineImmunologyPharmacology	2017	129
A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib Kristen N. Ganjoo, Víctor M. Villalobos, Aya Kamaya, Annals of Oncology Surgical OncologyLeast ImatinibGastrointestinal OncologyMedicineGastroenterology	2013	119
Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study Yoon‐Koo Kang, Suzanne George, Robin L. Jones, Journal of Clinical Oncology	2021	116
Phase II trial of the glycoprotein non-metastatic B-targeted antibody–drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group Lisa M. Kopp, Suman Malempati, Mark Krailo, European Journal of Cancer Phase Ii TrialMedicineImmunologyPathologyRecurrent Osteosarcoma Aost1521	2019	76
Synthesis and biological evaluation of aryl azide derivatives of combretastatin a-4 as molecular probes for tubulin Kevin G. Pinney, Maria P Mejia, Víctor M. Villalobos, Bioorganic & Medicinal Chemistry Bioorganic ChemistryBiochemistryNatural SciencesAryl Azide DerivativesMedicine	2000	75

Page 1